AAVantgarde Bio develops gene therapies utilizing proprietary Adeno-Associated Viral (AAV) vector technology to enable the delivery of large genes for the treatment of inherited retinal disorders. The company addresses the limitations of traditional AAV vectors, which restrict the payload size, thereby expanding the potential for genetic medicine in underserved patient populations.

AAVantgarde Bio has developed an engineered adeno‑associated virus (AAV) platform that can package and deliver transgenes larger than 5 kb to photoreceptor and retinal pigment epithelium cells, overcoming the size limitation of standard AAV vectors. The system provides high retinal transduction efficiency, sustained expression, and a GMP‑compatible manufacturing process, supporting clinical programs for Stargardt disease (ABCA4) and Usher 1B syndrome (MYO7A).

AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

AM Pharma is developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase, as an enzyme replacement therapy for adult hypophosphatasia (HPP). The subcutaneous treatment restores alkaline phosphatase activity, lowering disease‑related pyridoxal‑5′‑phosphate and inorganic pyrophosphate levels, which improves bone mineralization, muscle function, and pain. Phase 1b data show dose‑dependent normalization of HPP biomarkers and a favorable safety profile, positioning ilofotase alfa for Phase 2 trials to address the unmet need in adult HPP patients.

The startup develops targeted protein degradation therapeutics that utilize novel mechanisms to modulate the degradation of disease-related proteins. This approach aims to enhance therapeutic efficacy for a range of diseases by precisely regulating protein abundance linked to disease progression.

Anaveon is developing IL-2 complexes, specifically ANV419 and ANV600, which enhance effector T cell functions to improve immune responses in cancer treatment. The company addresses the need for safe and effective immunotherapies for patients with high unmet medical needs by utilizing protein engineering to optimize cytokine activity.

Azafaros develops therapeutic agents that target rare metabolic disorders through metabolic pathway modulation and advanced drug discovery techniques. The company provides effective treatment options for patients with unmet medical needs in this specialized healthcare segment.

Beacon Therapeutics develops AAV gene therapy to treat blinding retinal diseases, including X-Linked Retinitis Pigmentosa, by introducing functional copies of mutated genes into patients' cells. This approach aims to restore vision and improve the quality of life for individuals affected by these conditions.

Bicycle Therapeutics creates fully synthetic, bi‑cyclic peptide molecules that combine the high affinity of biologics with drug‑like pharmacokinetics, enabling precise targeting of protein‑protein interactions that are difficult for traditional small molecules or antibodies. Their platform delivers rapid tissue penetration, renal clearance, and flexible conjugation to payloads, supporting targeted drug conjugates and immune agonists for solid‑tumor oncology and a range of non‑oncology indications. The company partners with pharma, biotech, and academic groups to develop novel therapeutics for high‑unmet‑need disease targets.

BraveBand offers wearable technology designed for personal safety and group connection through stylish bracelets. Users can instantly send a vibration alert, or "BUZZ," to their designated party group when they need assistance. Friends can then use the companion app's compass feature to locate the sender quickly.

Calluna Pharma is developing therapies that specifically modulate immune pathways and remodel the extracellular matrix to target chronic inflammation and fibrosis. These therapies aim to reduce the impact of inflammatory diseases and enhance tissue repair, addressing significant health challenges associated with these conditions.

CatalYm is developing a monoclonal antibody, visugromab, that neutralizes GDF-15 to reverse immune resistance mechanisms in solid tumors, thereby enhancing anti-tumor immune responses. This approach aims to improve treatment outcomes for cancer patients who are non-responsive to existing therapies, addressing a significant gap in current immunotherapy effectiveness.

Citryll is developing CIT-013, a first-in-class monoclonal antibody that inhibits the formation of Neutrophil Extracellular Traps (NETs) and enhances their clearance, targeting a key mechanism in immune-mediated inflammatory diseases. The company focuses on treating conditions such as Rheumatoid Arthritis and Hidradenitis Suppurativa, where NETs contribute significantly to inflammation.

Complement Therapeutics develops novel therapies that modulate the complement system to address unmet needs in complement‑mediated diseases, most notably geographic atrophy in age‑related macular degeneration. Its pipeline includes an AAV‑based gene therapy (CTx001) for retinal complement dysregulation and protein‑based candidates for systemic conditions, supported by a mass‑spectrometry platform that quantifies multiple complement proteins from a single blood sample for patient stratification and trial monitoring.

Dyne Therapeutics develops nucleic acid therapies using its proprietary FORCE™ platform to enhance muscle tissue delivery for patients with genetically driven muscle diseases. The company focuses on creating targeted treatments that aim to halt or reverse the progression of serious muscle disorders.

Engrail Therapeutics develops precision-targeted therapeutics for patients with life-limiting neurological disorders by leveraging expertise in molecular mechanisms and neurocircuitry. The company aims to provide effective treatments that address the unmet medical needs of individuals suffering from these debilitating conditions.

Develops novel inhaled therapies targeting epithelial sodium channels (ENaC) to reduce mucus congestion in respiratory diseases like cystic fibrosis, asthma, and COPD. These treatments aim to decrease lung infections and improve respiratory function, addressing the underlying causes of chronic respiratory conditions affecting over 700 million people globally.

ENTR is an AI-powered formulation and nutrition labeling software that enables food, beverage, and supplement companies to efficiently manage ingredient and supplier data while generating regulatory-compliant nutrition labels. The platform minimizes manual data entry and reduces the risk of compliance penalties, streamlining workflows and accelerating product development.

Expedition Therapeutics is developing EXPD-101, an oral, once‑daily DPP1 inhibitor that selectively blocks neutrophil serine protease activation to reduce airway tissue damage and disease progression in COPD and other neutrophil‑driven respiratory conditions. The drug is designed for high potency, favorable pharmacokinetics, and a strong safety profile, with Phase 1 tolerability data and a global Phase 2 trial underway. It targets pharmaceutical partners, clinical researchers, and healthcare providers seeking disease‑modifying therapies for COPD, bronchiectasis, neutrophilic asthma, and related diseases.

F2 provides an AI platform specifically designed for private market investors to accelerate the investment decision process. The platform automates financial analysis by integrating proprietary institutional knowledge with live market data to uncover risks and validate assumptions. It enables teams to collaborate in real time and generate audit-ready, IC-ready reports quickly from data rooms.

Gate Bioscience is developing Molecular Gates, small molecule drugs that selectively block disease-causing extracellular proteins from being secreted by targeting the secretory translocon within cells. By preventing the emergence of these harmful proteins, the company aims to eliminate diseases linked to over 1,000 identified extracellular proteins.

Gen+ is a digital platform that provides leadership and meta-skills education for learners aged 9-14 and their teachers, utilizing a blended learning approach that combines online and in-person instruction. The program addresses the lack of standardized skills development in schools by equipping students with essential, transferable skills necessary for success in learning, work, and life.

Inven utilizes AI algorithms to analyze extensive data from various sources, enabling professionals in private equity, investment banking, and management consulting to identify high-potential companies and acquisition targets quickly. This technology significantly reduces the time spent on manual research, allowing users to source deals and gain market insights more efficiently.

The startup develops a precision medicine targeting cognitive impairment in schizophrenia by utilizing a human biology-based approach and a causal biomarker strategy to validate its mechanism of action. This research enables the identification of responder sub-populations, aiming to restore brain function in affected patients.